Cyclerion Therapeutics (CYCN) Stock Surges 160% on Korsana Merger Deal

TLDR

• Cyclerion Therapeutics (CYCN) surged over 160% in pre-market trading after announcing a merger with private biotech Korsana Biosciences
• The combined company will operate as Korsana Biosciences and trade on Nasdaq under the new ticker “KRSA”
• Pre-merger Cyclerion holders will own just 1.5% of the combined entity; Korsana holders will hold 98.5%
• Korsana secured a $380 million private investment led by Fairmount and Venrock Healthcare Capital Partners, with backing from J.P. Morgan, Janus Henderson, and Sanofi Ventures
• The lead drug KRSA-028 targets Alzheimer’s disease, with Phase 1 data expected mid-2027 and proof-of-concept data by end of 2027

---

Cyclerion Therapeutics announced on April 1, 2026, that it has entered into a definitive all-stock merger agreement with privately-held Korsana Biosciences. The news sent CYCN stock up more than 160% in pre-market trading.

Cyclerion Therapeutics, Inc., CYCN

The deal is a near-total reverse merger. Cyclerion’s existing holders will retain just 1.5% of the combined company, with Korsana’s shareholders taking 98.5%.

Once completed, Cyclerion will effectively cease to exist as a public entity. The combined company will operate under the Korsana Biosciences name and trade on Nasdaq under the ticker “KRSA.”

The transaction has already been approved by the boards of both companies. It is expected to close in the third quarter of 2026, pending stockholder approval, SEC registration effectiveness, and other standard closing conditions.

Backing the deal is a heavily oversubscribed private investment round totaling approximately $380 million. The round was led by Fairmount and Venrock Healthcare Capital Partners, with participation from Janus Henderson (JHG), J.P. Morgan Life Sciences Private Capital, and Sanofi Ventures (SNY).

That capital is intended to fund operations through 2029, giving the combined company runway to advance its lead program through key clinical milestones.

The Drug at the Center of the Deal

Korsana’s lead asset, KRSA-028, is a next-generation shuttled monoclonal antibody designed to treat Alzheimer’s disease. It targets amyloid beta and uses the company’s proprietary Therapeutic Targeting platform, which incorporates transferrin receptor and Fc engineering to improve brain delivery.

The therapy is designed for subcutaneous administration, which could make it easier to administer than current IV-based options. Around 60 million people worldwide live with Alzheimer’s disease.

Phase 1 healthy volunteer data is expected in mid-2027. Interim proof-of-concept data measuring amyloid plaque clearance in Alzheimer’s patients is targeted for the end of 2027.

Jonathan Violin, Korsana’s current CEO, will lead the combined company. Korsana’s Board of Directors will carry over, with Tomas Kiselak of Fairmount serving as chair.

Cyclerion’s Strategic Review

For Cyclerion, the deal caps a strategic review process. The company had been exploring options following earlier work on CYC-126, its treatment-resistant depression program.

The FDA had recently provided positive written feedback on Cyclerion’s planned Phase 2 study for CYC-126. The company had also signed a collaboration with Medsteer to advance a closed-loop anesthetic platform using EEG-guided technology for that program.

Those programs appear set to take a back seat as the combined entity focuses on Korsana’s Alzheimer’s pipeline. Wedbush Securities advised Korsana on the deal; Gemini Valuation Services advised Cyclerion.

Prior to today’s move, CYCN had been up roughly 15% over the past three months. The stock was trading around 59% below its 52-week high of $3.79 before the announcement.

The post Cyclerion Therapeutics (CYCN) Stock Surges 160% on Korsana Merger Deal appeared first on CoinCentral.